General Information of the Drug (ID: M6APDG04369)
Name
Apolipoprotein E
Synonyms
Apolipoprotein E, Bio-Technology General; Apo-A4, Bio-Technology General; Apo-E, Bio-Technology General; Apolipoprotein-A4, Bio-Technology General
    Click to Show/Hide
Status
Terminated
TTD Drug ID
D02ADJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Apolipoprotein E (APOE)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Apolipoprotein E (APOE) is a therapeutic target for Apolipoprotein E. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Apolipoprotein E through regulating the expression of Apolipoprotein E (APOE). [1], [2]
References
Ref 1 FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. J Exp Clin Cancer Res. 2022 Jan 28;41(1):42. doi: 10.1186/s13046-022-02254-z.
Ref 2 Clinical pipeline report, company report or official report of LipimetiX.